The Latest Breaking News from Vaccine

Should everyone eligible get the new omicron-specific COVID booster? Yes, absolutely. But we should not get lulled into the illusion that the fight against COVID is over and now comparable to preventing the flu.

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Following the death of the Queen, rumours began to spread online on everything from the nature of her passing to the colour of the BBC's banner.

It took scientists 30 years to create the first malaria vaccine, approved by the World Health Organization in 2021. A second, even better one is now almost ready to be deployed against the disease. Governments and philanthropies should be stepping up their funding to global health partners so they can…

Vaccine stocks Pfizer and Moderna could see some upside from their new Covid boosters, according to the September IBD/TIPP Poll.

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

The long march of religious liberty exemptions is gaining speed. The people who brought you contraceptive care exemptions and COVID rule and vaccine exemptions have now moved on to insurance for anti-HIV drugs. Last week, a federal district court held that a Christian employer is entitled to an exemption from…

Fainting and fatigue may signal onset of variant, experts say

‘Even having had Omicron, we’re not well protected from further infections,’ said Prof Danny Altmann

As the Biden administration asks Congress for additional federal dollars to fight infectious diseases, it faces a conundrum: pandemic fatigue.

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…